



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com


[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

PRODUCT INFORMATION



Mavorixafor Item No. 28439

CAS Registry No.: 558447-26-0
Formal Name: N¹-(1H-benzimidazol-2-ylmethyl)-N¹-
[(8S)-5,6,7,8-tetrahydro-8-quinolinyl]-
1,4-butanediamine
Synonyms: AMD 070, AMD 11070, X4P-001
MF: C₂₁H₂₇N₅
FW: 349.5
Purity: ≥95%
UV/Vis.: λ_{max}: 270, 277 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Mavorixafor is supplied as a crystalline solid. A stock solution may be made by dissolving the mavorixafor in the solvent of choice, which should be purged with an inert gas. Mavorixafor is soluble in DMSO.

Description

Mavorixafor is a chemokine (C-X-C motif) receptor 4 (CXCR4) antagonist (IC₅₀ = 13 nM in a radioligand binding assay).¹ It is selective for CXCR4 over chemokine (C-C motif) receptor 1 (CCR1), CCR2b, CCR4, CCR5, CXCR1, and CXCR2 (IC₅₀s = >10 μM for all). Mavorixafor reduces chemotaxis of CCRF-CEM T cells induced by chemokine (C-X-C motif) ligand 12 (CXCL12; IC₅₀ = 19 nM).² It inhibits fusion of CHO-K1 cells expressing gp120 to P4-P5 MAGI cells with an IC₅₀ value of 1.5 nM. It decreases HIV-1 NL4.3 viral replication in MT-4 cells and isolated human peripheral blood mononuclear cells (PBMCs; IC₅₀s = 2 and 9 nM, respectively).¹

References

1. Skerlj, R.T., Bridger, G.J., Kaller, A., *et al.* Discovery of novel small molecule orally bioavailable C-X-C chemokine receptor 4 antagonists that are potent inhibitors of T-tropic (X4) HIV-1 replication. *J. Med. Chem.* **53**(8), 3376-3388 (2010).
2. Mosi, R.M., Anastassova, V., Cox, J., *et al.* The molecular pharmacology of AMD11070: An orally bioavailable CXCR4 HIV entry inhibitor. *Biochem. Pharmacol.* **83**(4), 472-479 (2012).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 01/13/2020

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM